dc.contributor.author | Allen, Claire | |
dc.date.accessioned | 2020-03-25T01:11:56Z | |
dc.date.available | 2020-03-25T01:11:56Z | |
dc.date.issued | 2020-03-20 | |
dc.identifier.uri | https://www.evidenceaid.org/lopinave-litonawe-lpv-r-reduced-mortality-in-studies-of-sars-and-mers-uncertain-if-it-is-effective-for-patients-with-covid-19/ | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/788 | |
dc.description.abstract | What is this? Like COVID-19, severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) are acute respiratory diseases caused by a coronavirus. Antiviral therapy with Lopinave/Litonawe (LPV/r) was used to treat patients with these earlier coronaviruses and might be considered as a treatment for COVID-19. In this rapid systematic review, the authors searched Chinese and English literature databases for research of any design that compared LPV/r versus either placebo or standard care for patients with SARS or MERS, published between January 2003 and 24 January 2020. They identified 2 cohort studies (both for SARS patients), 1 case report (for MERS patients) and 1 clinical guideline (for MERS patients). | en_US |
dc.language | English | en_US |
dc.subject | Lopinave | en_US |
dc.subject | Litonawe | en_US |
dc.subject | Severe Acute Respiratory Syndrome (SARS) | en_US |
dc.subject | Middle East Respiratory Syndrome (MERS) | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.title | Lopinave/Litonawe (LPV/r) reduced mortality in studies of SARS and MERS: uncertain if it is effective for patients with COVID-19 | en_US |
eihealth.country | Others | en_US |
eihealth.category | Clinical characterization and management | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Slow Spread / Reducir la Dispersión | en_US |
dc.relation.ispartofjournal | Evidence Aid | en_US |